Article Text

PDF
Concise report
The minimally important difference and patient acceptable symptom state for the Raynaud's condition score in patients with Raynaud's phenomenon in a large randomised controlled clinical trial
  1. Puja P Khanna1,
  2. Paul Maranian1,
  3. Jeff Gregory2,
  4. Dinesh Khanna1,3
  1. 1Division of Rheumatology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California, USA
  2. 2MediQuest Therapeutics, Inc, Bothell, Washington, DC, USA
  3. 3Department of Health Services, School of Public Health, University of California at Los Angeles, Los Angeles, California, USA
  1. Correspondence to Dr Dinesh Khanna, Division of Rheumatology, Department of Medicine, David Geffen School of Medicine, 1000 Veteran Avenue, Rm 32-59 Rehabilitation Building, Los Angeles, CA 90095, USA; dkhanna{at}mednet.ucla.edu

Abstract

Background The Raynaud's condition score (RCS) is a validated outcome measure for Raynaud's phenomenon (RP).

Objective To assess the minimally important difference (MID) and patient acceptable symptom state (PASS) for RCS in patients with RP.

Subjects and methods Patients with active RP (n=162) (mean RCS >25 (0–100 visual analogue scale) participated in a placebo-controlled, crossover randomised clinical trial (RCT). Data from the two treatment groups were combined for this analysis. Retrospective and prospective anchors were administered during the RCT. MID groups were defined as the group who reported being somewhat better (anchor #1) and a one-step change from “unbearable” to “very severe”, etc (anchor #2). Patients were considered to have achieved PASS if they rated their Raynaud's condition as “very mild” or “mild” at the last study visit.

Results The mean age of participants was 48.9 years and the mean baseline RCS was 46.4 points. The RCS change score for the MID improvement group ranged from −13.9 to −14.3 points and PASS estimate was 34.0 points.

Conclusion The MID and PASS estimates for RCS are 14–15 points for improvement and 34 points, respectively, on a 0–100 scale in a large RCT of patients with active RP. This information can aid in interpreting RCS in future RP trials.

Statistics from Altmetric.com

Footnotes

  • Competing interests JG is an employee of MediQuest Therapeutics, Inc, sponsor of the clinical trial.

  • Ethics approval Obtained from US IRB.

  • Patient consent Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.